FUNDC1 and craniosynostosis 4: Shen et al. demonstrated in a mouse model of CRS-4 that dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), reduced myocardial injury through inhibition of FUNDC1-dependent mitophagy which suggests that CRS-4 may render FUNDC1-dependent mitophagy defective via the pyruvate kinase isozyme (PKM2)/protein phosphatase (PP1)/FUNDC-1 mitophagy pathway [11].